DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
About this trial
The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every 3 weeks, or every 4 weeks. Researchers will then compare the outcomes among these three groups.
Eligibility criteria
Qualifiers
The subject is an adult,
Has a diagnosis of AE,
Receives dupilumab 300 mg q2w for the treatment of AE,
Has controlled disease according to the Treat-to-Target criteria,
Disqualifiers
The subjects uses or initiates another systemic immunomodulating therapy for AE or another diagnosis.
Trial design
Treatments tested in this trial
- Dupilumab
Treatment groups
216 Participants
are divided into 3 treatment groupsSponsors and collaborators
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Lead sponsor
Erasmus Medical Center
Collaborator
Prothya Biosolutions
Collaborator
Source ClinicalTrials.gov